Therefore, renin–angiotensin–aldosterone system (RAAS) inhibitors remain the first-choice treatment to prevent progression of CKD; however, their use is limited by the risk of hyperkalemia and acute kidney injury [23]. Here, REN is linked to Hyperkalemia.